You are here

METHODS ARE BEING INVESTIGATED TO INCREASE THE EFFICACY OF PRODUCING MONOCLONAL ANTIBODIES TO TRACE QUANTITIES OF PEPTIDES AND PROTEINS THAT ARE OF HIGH VALUE TO SCIENCE AND INDUSTRY.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 2925
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1985
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2121 N. 35th St.
Seattle, WA 98103
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN FORSTROM
 PRINCIPAL INVESTIGATOR
 (206) 632-4036
Business Contact
Phone: () -
Research Institution
N/A
Abstract

METHODS ARE BEING INVESTIGATED TO INCREASE THE EFFICACY OF PRODUCING MONOCLONAL ANTIBODIES TO TRACE QUANTITIES OF PEPTIDES AND PROTEINS THAT ARE OF HIGH VALUE TO SCIENCE AND INDUSTRY. THE RESEARCH WILL LEAD TO THE DEVELOPMENT OF DIAGNOSTIC AND THERAPEUTIC ANTIBODIES HAVING CHARACTERISTICS SUPERIOR TO THOSE CURRENTLY AVAILABLE. SUBMICROGRAM LEVELS OF PROTEINS AND SMALL PEPTIDES WILL BE BOUND TO NITROCELLULOSE FILTER MEMBRANES AND USED TO IMMUNIZE MICE. THE SPECIFIC AIMS OF PHASE I ARE TO OBTAIN INFORMATION CONCERNING THE: 1.MINIMUM LEVEL OF IMMUNOGEN REQUIRED FOR AN IMMUNE RESPONSE5.IMMUNE RESPONSE TOWARD SMALL PEPTIDES ADSORBED TO NITROCELLULOSE. PHASE II RESEARCH WILL INVOLVE AN EXPANDED INVESTIGATION OF THE METHODOLOGICAL APPROACH DEVELOPED IN PHASE I, ESPECIALLY IN THE AREA OF PEPTIDE IMMUNOGENS. ALSO, ANTIBODIES OF COMMERCIAL VALUE WILL BE DEVELOPED AGAINST HUMAN PROTEINS AVAILABLE TO ZYMOGENETICS WHICH HAVE DIAGNOSTIC AND THERAPEUTIC VALUE. THE SUCCESS OF THIS WORK WILL PROVIDE SIGNIFICANT CONTRIBUTIONS TO BIOTECHNOLOGY AND HUMAN HEALTH CARE.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government